drugdeliverybusiness2d
Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.
Trinity Biotech announces breakthrough in CGM technology
DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for its ...